Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
This weight-loss drug stock could deliver a 90% return in 2025
Metsera Inc (NASDAQ: MTSR) has been pushing to the upside since its debut on Nasdaq on January 31. But analysts are convinced ...
Insider Monkey3d
10 Best Weight Loss Drug Stocks to Buy According to Analysts
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is expanding its presence in the weight loss and metabolic disease sector through a strategic collaboration with Metsera, Inc., announced in October 2024.
MarketWatch7d
Why this newly public biotech could become a force in obesity treatments
Metsera Inc. MTSR, a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in ...
BioSpace5d
Kallyope Discreetly Drops Disappointing Data for Oral Obesity Candidate
While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...
Seeking Alpha7d
Metsera started at buy at Guggenheim on obesity treatment potential
Guggenheim has initiated Metsera at buy saying that the ... excellent 12-week weight loss seen in a phase 2a trial, and an improved tolerability profile. "If 097i demonstrates acceptable ...
Investing7d
Wall Street bullish on Metsera following January IPO on obesity drug pipeline
Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference
A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...